Workflow
来那度胺胶囊
icon
Search documents
双鹭药业的“中年危机”
Bei Jing Shang Bao· 2025-05-15 12:26
Core Viewpoint - On its 30th anniversary, Shuanglu Pharmaceutical is facing a historic turning point, reporting a net loss of approximately 74.07 million yuan for 2024, marking its first annual loss since its listing in 2004 [1][4]. Financial Performance - In 2024, Shuanglu Pharmaceutical achieved an operating revenue of approximately 660 million yuan, a year-on-year decline of 35.15%, with a corresponding net profit of -74.07 million yuan, transitioning from profit to loss [4]. - The company had previously seen net profits exceeding 100 million yuan since 2007, peaking at 695 million yuan in 2014, and fluctuating between 200 million and 500 million yuan from 2020 to 2023 [4]. - In the first quarter of 2024, the company reported an operating revenue of approximately 169 million yuan, down 31.1%, and a net profit of approximately 45.97 million yuan, down 34.46% [4]. Product Sales Decline - Multiple key products experienced significant sales declines in 2024, with the oncology and immune regulation products generating sales of 276 million yuan, accounting for 42.69% of total sales, down 27.69% year-on-year [6]. - The sales of the previously promising product, Lenalidomide, accounted for only 4.89% of the oncology product category, with a staggering year-on-year decline of 77.22% [6][7]. - Other product categories, including anti-infection, trauma repair, and cardiovascular products, also saw sales declines of 48.42%, 30.95%, and 33.92% respectively [7]. Financial Asset Impact - The decline in financial assets, particularly the fair value changes in securities investments, significantly impacted the company's performance, with a total loss of approximately 178 million yuan from its holdings in Fosun Pharma, Shouyao Holdings, and Xinghao Pharma [9]. - The fair value changes for these stocks were -22.94 thousand yuan, -161 million yuan, and -16.14 million yuan respectively, contributing to the overall financial downturn [9]. Future Outlook - The company plans to increase R&D investment and has developed a strong product pipeline in oncology, liver disease, antiviral, metabolic regulation, and cardiovascular fields, while also exploring new areas such as diabetes and ophthalmology [5]. - The chairman expressed optimism that the company will recover its performance, viewing 2025 as a year of both challenges and opportunities [5][10].
山东步长制药股份有限公司关于全资子公司经营范围变更的公告
Core Viewpoint - The announcement details the changes in the business scope of the wholly-owned subsidiaries of Shandong Buchang Pharmaceutical Co., Ltd., specifically Baoding Tianhao Pharmaceutical Co., Ltd. and Shaanxi Buchang Pharmaceutical Co., Ltd., aimed at improving operational management [1][5]. Group 1: Business Scope Changes - Baoding Tianhao's previous business scope included the production of various pharmaceutical forms, while the new scope allows for broader technical services and drug production [1][2]. - Shaanxi Buchang's business scope has also been expanded to include additional services such as solar energy technology services and contract energy management, alongside its existing pharmaceutical production and wholesale activities [2]. Group 2: Financial Data - As of December 31, 2023, Baoding Tianhao reported total assets of 488.63 million, total liabilities of 319.97 million, and a net asset of 168.66 million, with an annual revenue of 1.21 billion and a net profit of 156.36 million [3]. - For the first nine months of 2024, Baoding Tianhao's total assets were 432.43 million, total liabilities were 288.80 million, net assets were 143.62 million, with a revenue of 906.63 million and a net profit of 131.32 million [3]. - Shaanxi Buchang reported total assets of 3.88 billion, total liabilities of 2.62 billion, and net assets of 1.26 billion as of December 31, 2023, with an annual revenue of 3.34 billion and a net profit of 548.81 million [4]. - As of September 30, 2024, Shaanxi Buchang's total assets were 3.87 billion, total liabilities were 2.98 billion, net assets were 882.65 million, with a revenue of 2.06 billion and a net profit of 254.70 million [4]. Group 3: Authorization and Management - The company has authorized its chairman and president to handle all procedures related to the changes in business scope, including signing relevant documents and submitting government approval applications [4].